AG490 inhibits G1-S traverse in BALB/c-3T3 cells following either mitogenic stimulation or exogenous expression of E2F-1

Molecular Cancer Therapeutics

Volumn 3, Issue 2, 2004, Pages 205-213

  Savell, Jason ^a   Ma, Yihong ^a   Morrow, Kristin S ^a   Jove, Richard ^a   Olashaw, Nancy ^a   Moseley, Pope L ^b   Cress, W Douglas ^a   Wharton, Walker ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT PROTEIN; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; GROWTH INHIBITION; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 4444314785     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev, 1998;12:2245-62.
2. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth & Differ, 1998;9:585-93.
3. Nevins JR, Leone G, DeGregori J, Jakoi L. Role of Rb/E2F pathway in cell growth control. J Cell Physiol, 1997;173:233-6.
4. 1 phase of the cell cycle. Cell, 1991;65:701-13.
5. Winston JT, Pledger WJ. Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. Mol Biol Cell, 1993;4:1133-44.
6. cip1. Mol Cell Biol, 2000; 20:8748-57.
7. kip1 by platelet-derived growth factor and plasma factors in density-arrested fibroblasts. J Biol Chem, 1996;271: 11253-60.
8. kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol Cell Biol, 1996;16:4327-36.
9. Kip1 accumulation during the cell cycle. Science, 1996;271:1861-74.
10. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science, 1995;269:682-5.
11. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J, 1997;16:5334-44.
12. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol, 1998;18:753-61.
13. 1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell, 2000;101:79-89.
14. He Y, Armanious MK, Thomas MJ, Cress WD. Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene, 2000;19:3422-33.
15. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol, 2000;20:3626-32.
16. Moberg K, Starz MA, Lees JA. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol, 1996;16:1436-49.
17. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev, 1994;8:1514-25.
18. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol, 1993;13:1610-8.
19. Croxton RL, Me Y, Cress WD. Differences in DNA binding properties between E2F1 and E2F4 specify repression of the Mcl-1 promoter. Oncogene, 2002;21:1563-7.
20. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA, 1997;94:7245-50.
21. Tao Y, Kassatly RF, Cress WD, Horowitz JM. Subunit composition determines E2F DNA-binding site specificity. Mol Cell Biol, 1997;17: 6994-7007.
22. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature, 1996;379:645-8.
23. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994;264:1415-21.
24. Dalton WS, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol, 1999;26:23-7.
25. 1 and S phase. Exp Cell Res, 1998;241:340-51.
26. Pledger WJ, Stiles CD, Antoniades HN, Scher CO. Induction of DNA synthesis in BALB/c 3T3 cells by serum components: reevaluation of the commitment process. Proc Natl Acad Sci USA, 1977;74:4481-5.
27. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the src oncoprotein. Science, 1995;269:81-3.
28. Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J, 1990;9:4477-84.
29. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene, 2000;19:2474-88.
30. Darnell JE. STATs and gene regulation. Science, 1997;277:1630-5.
31. Wang YZ, Wharton W, Garcia R, Kraker A, Jove R, Pledger WJ. Activation of Stat3 preassembled with platelet-derived growth factor β receptors requires src kinase activity. Oncogene, 2000;19:2075-85.
32. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated myc expression is required for src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA, 2001; 98:7319-24.
33. Dong F, Cress WD, Agrawal D, Pledger WJ. The role of cyclin D3-dependent kinase in the phosphorylation of p130 in mouse BALB/c 3T3 cells. J Biol Chem, 1998;273:6190-5.
34. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66.
35. kip1. Mol Biol Cell, 2000;11:2117-30.
36. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature, 1994;372:570-3.
37. Wharton W, Savell J, Cress WD, Seto E, Pledger WJ. Inhibition of mitogenesis in BALB/c-3T3 cells by trichostatin A: multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J Biol Chem, 2000;275:33981-7.
38. Grana X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene, 1998;17:3365-83.
39. kip1 in BALB/c 3T3 cells. Mol Biol Cell, 1998;9:2081-92.
40. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol, 2000;20:3633-9.
41. Heldin CH. Structural and functional studies on platelet-derived growth factor. EMBO J, 1992;11:4251-9.
42. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev, 1999;79:1283-316.
43. Fambrough D, McClure K, Kazlauskas A, Lander ES. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell, 1999;97:727-41.
44. 1 transition in mouse fibroblasts. Semin Cancer Biol, 1990;1:37-46.
45. Cochran BH. The molecular action of platelet-derived growth factor. Adv Cancer Res, 1985;45:183-216.
46. 1 progression in competent BALB/c-3T3 cells. Exp Cell Res, 1982;141:107-15.
47. Vignais ML, Gilman M. Distinct mechanisms of activation of Stat1 and Stat3 by platelet-derived growth factor receptor in a cell-free system. Mol Cell Biol, 19:3727-35.
48. 1-phase progression. Genes Dev, 1999; 13:1501-12.
49. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. Cyclin A/cdk2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol, 1994;14:8420-31.
50. 1 cyclin-dependent kinase activity. Genes Dev, 1995;9:2873-87.